These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 19004654

  • 21. Periodontal assessment of postmenopausal women receiving risedronate.
    Palomo L, Bissada NF, Liu J.
    Menopause; 2005; 12(6):685-90. PubMed ID: 16278611
    [Abstract] [Full Text] [Related]

  • 22. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD, Hanley DA, Lorraine JK, Yu M.
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [Abstract] [Full Text] [Related]

  • 24. Monitoring of Risedronate by biochemical bone markers in clinical practice.
    Bunyaratavej N.
    J Med Assoc Thai; 2005 Oct; 88(suppl 5):S34-6. PubMed ID: 17500121
    [Abstract] [Full Text] [Related]

  • 25. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 26. [The interest of biochemical markers of bone turnover for monitoring treatment of postmenopausal osteoporosis].
    Kalaï E, Bahlous A, Makdouli A, Sahli H, Klouz A, Lakhal M, Sellami S, Abdelmoula J.
    Tunis Med; 2008 Feb; 86(2):122-7. PubMed ID: 18444527
    [Abstract] [Full Text] [Related]

  • 27. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
    Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, Horio M, Imai E, Hori M, Ito T.
    Nephrol Dial Transplant; 2007 Jun; 22(6):1601-7. PubMed ID: 17124283
    [Abstract] [Full Text] [Related]

  • 28. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV, Fuster D, Pedroso S, Diekmann F, Campistol JM, Rubí S, Oppenheimer F.
    Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
    [Abstract] [Full Text] [Related]

  • 29. Comparing the effect of short term post meals and bedtime calcium supplementation on the C-terminal telopeptide crosslinks and PTH levels in postmenopausal osteopenic women.
    Chuengsamarn S, Suwanwalaikorn S.
    J Med Assoc Thai; 2005 Jun; 88 Suppl 1():S12-20. PubMed ID: 16858933
    [Abstract] [Full Text] [Related]

  • 30. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
    D'Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G.
    J Bone Miner Res; 2008 Mar; 23(3):373-9. PubMed ID: 17967134
    [Abstract] [Full Text] [Related]

  • 31. Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study.
    Łukaszkiewicz J, Karczmarewicz E, Płudowski P, Jaworski M, Czerwiński E, Lewiński A, Marcinowska-Suchowierska E, Milewicz A, Spaczyński M, Lorenc RS, EPOLOS Group.
    Med Sci Monit; 2008 Dec; 14(12):PH65-70. PubMed ID: 19043376
    [Abstract] [Full Text] [Related]

  • 32. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
    Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H.
    J Bone Miner Metab; 2004 Dec; 22(5):469-78. PubMed ID: 15316868
    [Abstract] [Full Text] [Related]

  • 33. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
    Yanik B, Bavbek N, Yanik T, Inegöl I, Kanbay M, Turgut FH, Uz E, Akçay A.
    Ren Fail; 2007 Dec; 29(4):471-6. PubMed ID: 17497471
    [Abstract] [Full Text] [Related]

  • 34. Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.
    Ozgocmen S, Kaya H, Fadillioglu E, Yilmaz Z.
    Arch Med Res; 2007 Feb; 38(2):196-205. PubMed ID: 17227729
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin.
    Gulseren A, Peyman B, Pinar A.
    Panminerva Med; 2011 Jun; 53(2):75-80. PubMed ID: 21659972
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy.
    Kumm J, Ivaska KK, Rohtla K, Vaananen K, Tamm A.
    Scand J Clin Lab Invest; 2008 Jun; 68(6):459-63. PubMed ID: 18609099
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.